Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Connective tissue disease in children.

Robert L Buka1, Bari B Cunningham

  • 1Children's Hospital and Health Center San Diego, University of California San Diego, 8010 Frost Street, Suite 602, San Diego, CA 92123, USA. rbuka@md.northwestern.edu

Pediatric Annals
|March 29, 2005
PubMed
Summary

New biologic therapies targeting cell-mediated inflammation show promise for treating autoimmune connective tissue diseases. These agents offer a potentially improved side-effect profile compared to traditional treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcription restores DNA repair to heterochromatin, determining regional mutation rates in cancer genomes.

Cell reports·2014
Same author

Pulsed dye laser for the treatment of macular amyloidosis: a case report.

Cutis·2014
Same author

Photodynamic therapy in a teenage girl with xeroderma pigmentosum type C.

Pediatric dermatology·2012
Same author

5% 5-Fluorouracil cream for treatment of verruca vulgaris in children.

Pediatric dermatology·2009
Same author

Surgical pearl: the pendulum or "scoop" biopsy.

Clinical medicine & research·2008
Same author

Ectopic acanthosis nigricans occurring in a child after syndactyly repair.

Cutis·2008

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Connective tissue diseases involve autoimmune-driven, cell-mediated inflammation.
  • Understanding the cytokine cascade is crucial for therapeutic development.

Purpose of the Study:

  • To review the expanding therapeutic options for connective tissue diseases.
  • To highlight the role of biologic agents in targeting cell-mediated inflammation.

Main Methods:

  • Review of current and emerging biologic agents.
  • Discussion of their mechanisms of action in autoimmune conditions.
  • Examination of clinical trial data for conditions like juvenile SLE and psoriatic arthritis.

Main Results:

  • Biologic agents like etanercept, alefacept, infliximab, efaluzimab, and adalimumab are effective in adult psoriasis.

Related Experiment Videos

  • Etanercept has a decade of successful use in juvenile rheumatoid arthritis.
  • Ongoing trials are evaluating these biologics for juvenile SLE, psoriasis, and psoriatic arthritis.

    • Conclusions:

    • Biologic agents targeting cell-mediated inflammation offer significant therapeutic potential.
    • These agents demonstrate an improved side-effect profile compared to corticosteroids.
    • Biologics are poised to be central to future targeted therapies for complex immunologic diseases.